EDAP TMS SA - Q1 2025 Financial Summary
Business Context and Reporting Period
This Form 6-K reports unaudited consolidated financial results for EDAP TMS SA for the three months ended March 31, 2025. EDAP is a global leader in robotic energy-based therapies, primarily focused on the Focal One Robotic HIFU System for prostate cancer treatment. The period includes significant clinical milestones, including the presentation of final FARP trial results and the launch of the Focal One i system.
Key Financial Metrics
| Metric | Q1 2025 (EUR) | Q1 2024 (EUR) | Change |
|---|---|---|---|
| Total Revenue | 13.6 million | 14.9 million | -9.1% |
| HIFU Revenue | 6.2 million | 5.8 million | +6.8% |
| Non-Core Revenue | 7.4 million | 9.1 million | -18.7% |
| Gross Profit | 5.7 million | 6.4 million | -10.8% |
| Gross Margin | 42.0% | 42.8% | -0.8 pts |
| Operating Loss | (6.0) million | (4.8) million | -25.0% |
| Net Loss | (7.1) million | (4.5) million | -57.8% |
| Net Loss Per Share | (0.19) | (0.12) | -58.3% |
| Cash & Equivalents | 22.8 million | 29.8 million (Dec '24) | -23.5% |
| Operating Cash Flow | (5.1) million | (13.6) million (TTM) | N/A |
Note: USD figures provided in the filing are approximate translations. Debt consists of short-term borrowings of EUR 5.7 million and long-term debt of EUR 1.6 million as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue declined 9.1% year-over-year, driven by a strategic reduction in non-core businesses (ESWL and Distribution), which fell 18.7%. Conversely, the core HIFU business grew 6.8%.
- System Placements: The company achieved a record nine Focal One system placements in Q1 2025, compared to five in Q1 2024. Six of these were recognized in revenue during the quarter.
- Expense Growth: Operating expenses increased to EUR 11.7 million from EUR 11.2 million, primarily due to focused investments in the HIFU segment and R&D.
- Currency Impact: Net loss widened significantly, partially exacerbated by a net currency exchange loss of EUR 0.96 million in Q1 2025, compared to a gain of EUR 0.24 million in Q1 2024.
Guidance, Outlook, and Management Commentary
- 2025 Guidance: Management reiterated full-year 2025 guidance, expecting core HIFU revenue growth of 16% to 25% and non-core revenue declines of 20% to 25%.
- Clinical Catalysts: The FARP randomized controlled trial demonstrated non-inferiority of focal ablation versus radical prostatectomy at 36 months, providing Level 1 evidence for first-line treatment. The company also received CE Mark designation for treating deep infiltrating endometriosis.
- Product Innovation: Launched the Focal One i system with enhanced imaging compatibility (PSMA PET, ExactVu) and remote proctoring capabilities. Successfully performed the world's first remote transcontinental procedure.
- Liquidity: Cash reserves decreased to EUR 22.8 million. Operating cash flow was negative EUR 5.1 million for the quarter, though an improvement over the trailing twelve-month burn rate.
Investor Verification Checklist
- Verify the conversion of the nine Focal One system placements into future recurring revenue streams (service and RPP).
- Monitor the impact of the FARP trial results on adoption rates in the U.S. and European markets in subsequent quarters.
- Assess the timeline for the phase-out of non-core ESWL and Distribution businesses to confirm the trajectory toward pure-play HIFU profitability.
- Review the burn rate relative to the EUR 22.8 million cash balance to determine runway without additional financing.
- Confirm the commercial uptake of the new Focal One i system features, specifically remote capabilities and AI integration.